Phase 1 trial of wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer

Journal of Immunotherapy

Volumn 34, Issue 1, 2011, Pages 92-99

  Kaida, Miho ^a,b   Morita Hoshi, Yuriko ^a   Soeda, Atsuko ^a   Wakeda, Takako ^a   Yamaki, Yuni ^a   Kojima, Yasushi ^a   Ueno, Hideki ^a   Kondo, Shunsuke ^a   Morizane, Chigusa ^a   Ikeda, Masafumi ^a   Okusaka, Takuji ^a   Takaue, Yoichi ^a   Heike, Yuji ^a  

^a National Cancer Research Center Hospital   (Japan)

^b KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

biliary tract cancer; gemcitabine; pancreatic cancer; WT1 peptide vaccine

Indexed keywords

ARGINYLMETHIONYLPHENYLALANYLPROLYLASPARAGINYLALANYLPROLYLTYROSYLLEUCINE; BIOLOGICAL MARKER; CYSTEINYLTYROSYLTHREONYLTRYPTOPHYLASPARAGINYLGLUTAMINYLMETHIONYLASPARAGINYLLEUCINE; GEMCITABINE; HLA A ANTIGEN; MONTANIDE ISA 51; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BILE DUCT CANCER; BILIARY TRACT CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EXTRAHEPATIC BILE DUCT CANCER; FATIGUE; FEMALE; FOLLOW UP; GALLBLADDER CANCER; GASTROMEGALY; HUMAN; HUMAN CELL; HYPOALBUMINEMIA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; LEUKOPENIA; LYMPHADENOPATHY; MALE; MIXED LYMPHOCYTE CULTURE; NAUSEA; NEUTROPENIA; OPTIMAL DRUG DOSE; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SKIN NODULE; SKIN ULCER; STOMACH DISEASE; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BILIARY TRACT NEOPLASMS; CANCER VACCINES; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; VACCINES, SUBUNIT;

EID: 78650667121     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181fb65b9     Document Type: Article

References (30)

1. Bergmann L, Miething C, Maurer U, et al. High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood. 1997;90:1217-1225.
2. Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89:1405-1412.
3. Oji Y, Ogawa H, Tamaki H, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194-204.
4. Campbell CE, Kuriyan NP, Rackley RR, et al. Constitutive expression of the Wilms tumor suppressor gene (WT1) in renal cell carcinoma. Int J Cancer. 1998;78:182-188.
5. Oji Y, Nakamori S, Fujikawa M, et al. Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma. Cancer Sci. 2004;95:583-587. (Pubitemid 39089639)
6. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19:804-814.
7. Gaiger A, Reese V, Disis ML, et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480-1489.
8. Tsuboi A, Oka Y, Ogawa H, et al. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination. J Clin Immunol. 2000;20:195-202. (Pubitemid 30485880)
9. Oka Y, Tsuboi A, Elisseeva OA, et al. WT1 as a novel target antigen for cancer immunotherapy. Curr Cancer Drug Targets. 2002;2:45-54.
10. Scheibenbogen C, Letsch A, Thiel E, et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood. 2002;100: 2132-2137.
11. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia. 2003;17:1301-1312.
12. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009; 15:5323-5337.
13. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood. 2009;113:6541-6548.
14. Ohno S, Kyo S, Myojo S, et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Res. 2009;29:4779-4784.
15. Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA. 2004;101:13885-13890.
16. Morita S, Oka Y, Tsuboi A, et al. A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. Jpn J Clin Oncol. 2006;36:231-236.
17. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood. 2008;111:236-242.
18. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403-2413.
19. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960-1966.
20. Pasetto LM, D'Andrea MR, Falci C, et al. Gemcitabine in advanced biliary tract cancers. Crit Rev Oncol Hematol. 2007;61:230-242.
21. Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273-1281.
22. Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer. 2006;107:676-685.
23. Yanagimoto H, Mine T, Yamamoto K, et al. Immunological evaluation of personalized peptide vaccination with gemcita-bine for pancreatic cancer. Cancer Sci. 2007;98:605-611.
24. Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 2010;40:573-579.
25. Matsuno S, Egawa S, Unno M. R0 resection for ductal pancreatic cancer - Japanese experience. Am J Surg. 2007;194: S110-S114.
26. Soeda A, Morita-Hoshi Y, Makiyama H, et al. Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer. Jpn J Clin Oncol. 2009;39:797-806.
27. Soeda A, Morita-Hoshi Y, Kaida M, et al. Long-term administration of Wilms tumor-1 peptide vaccine in combination with gemcitabine causes severe local skin inflammation at injection sites. Jpn J Clin Oncol. 2010. In Press.
28. Longmate J, York J, La Rosa C, et al. Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes. Immunogenetics. 2001;52:165-173.
29. Morita Y, Heike Y, Kawakami M, et al. Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation. Int J Cancer. 2006;119:1360-1367. (Pubitemid 44258812)
30. Sudo T, Kamikawaji N, Kimura A, et al. Differences in MHC class I self peptide repertoires among HLA-A2 subtypes. J Immunol. 1995;155:4749-4756.